March 8, 2022
“Russia has threatened to close a major gas pipeline to Germany and warned of $300 oil prices if the West goes ahead with a ban on its energy exports. “It is absolutely clear that a rejection of Russian oil would… Continue Reading…
February 15, 2022
“…The Dow jumped about 400 points, or 1%, helped by a 3% jump in Boeing. The S&P 500 climbed 1.5% and the technology-heavy Nasdaq Composite advanced 1.9%. All three major benchmarks were down in the three prior sessions. The S&P… Continue Reading…
January 13, 2022
“Total federal tax collections in the first three months of fiscal 2022—October through December—set a record as they topped $1 trillion, hitting $1,051,873,000,000, according to the Monthly Treasury Statement released today. Prior to this year, the most the federal government had… Continue Reading…
December 16, 2021
“With inflation now running at its fastest pace in nearly 40 years and showing no signs of slowing down, the Federal Reserve on Wednesday abandoned its wait-and-see strategy and indicated that it could begin stepping on the economic brakes soon.… Continue Reading…
September 27, 2021
“A rebound in oil prices — and oil stocks — presents an unexpected opportunity for investors to collect some healthy dividend checks while fundamentals continue to improve. On Friday, oil prices rose for a third straight week near three-year highs… Continue Reading…
August 25, 2021
“Samsung Group has unveiled a 240 trillion won ($205 billion) expansion that will entail hiring 40,000 people over three years, a sprawling investment blueprint intended to build the South Korean conglomerate’s lead in next-generation technologies…” https://finance.yahoo.com/news/samsung-create-10-000-jobs-060421527.html I hate to say… Continue Reading…
July 19, 2021
“Ambrx Biopharma (AMAM)… This new biopharma stock has a Strong Buy rating from the analyst consensus, based on 3 positive reviews so far. The shares are priced at $19.56 and their $39.50 average target suggests room for an upside of 101%… Continue Reading…
March 19, 2021
“Splunk, Inc. (SPLK)… The majority of the Street concurs, as among the 17 analysts to have published a call on SPLK over the last 3 months, 10 say Buy and 7 suggest Hold. SPLK’s Moderate Buy consensus rating is accompanied… Continue Reading…
December 14, 2020
“Vertex Pharmaceuticals (VRTX)… Overall, it appears that Wall Street agrees with Tenthoff. VRTX shares have a Strong Buy analyst consensus rating, based on 14 Buys and 4 Holds. The stock’s $287.50 average price target suggests it has room for 24% growth… Continue Reading…
Recent Comments